文献速递浆细胞疾病

中枢神经系统多发性骨髓瘤:希腊骨髓瘤研究组的真实世界多机构研究

Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group.
PubMed 文献 · Am J Hematol · 2024-07-02

该研究在2000至2022年间从4352例多发性骨髓瘤(MM)患者中识别出54例(1.2%)中枢神经系统多发性骨髓瘤(CNS-MM),并与无CNS-MM的匹配对照组比较。中位至CNS-MM时间为28个月,髓外浸润(EMI)是CNS-MM最强预测因素(OR 6.3);CNS-MM患者中位总生存(OS)为43个月 vs 对照组60个月(P<.001)。CNS-MM后中位OS仅4个月,2016年后治疗者中位OS为12个月。

要点

  • CNS-MM占MM的1.2%(54/4352),中位至发生时间28个月,6/54在MM诊断时即存在CNS-MM。
  • EMI是CNS-MM最强预测因素(OR 6.3),也是CNS-MM后OS最强负面预测因素(P=.005;HR 2.9)。
  • CNS-MM患者中位OS 43个月 vs 对照60个月(P<.001);CNS-MM后中位OS 4个月,2016年后治疗者12个月。

核心结论

  • 该真实世界大系列显示CNS-MM患者生存仍差,但2016年后治疗对OS有积极影响,与现代化抗骨髓瘤治疗疗效相关。
  • EMI显著增加CNS-MM发生概率及CNS-MM后死亡风险,提示这些患者可能需要CNS预防。

研究设计与样本

  • 希腊骨髓瘤研究组的真实世界多机构研究,2000至2022年间共纳入4352例MM患者,识别出54例(1.2%)CNS-MM患者。
  • 采用无CNS-MM的MM患者作为匹配对照组进行比较。

主要发现

  • CNS-MM患者中位年龄63岁,中位至CNS-MM时间28个月,6/54在MM诊断时发生CNS-MM。
  • 异常乳酸脱氢酶(LDH)、高危细胞遗传学和髓外浸润(EMI,即软组织浆细胞瘤和/或浆细胞白血病(PCL))在CNS-MM组较对照组更常见(P<.05);13/54在CNS-MM时存在PCL。
  • 大多数患者为软脑膜浸润(LMI)(66%),26%的CNS-MM患者无系统性骨髓瘤;EMI是CNS-MM最强预测因素(OR 6.3)。
  • CNS-MM患者中位OS为43个月(95%CI 32-54)vs 对照组60个月(95%CI 38-82)(P<.001);CNS-MM后中位OS为4个月(95%CI 2.6-5.4),2016年后治疗者中位OS为12个月。
  • EMI是CNS-MM后OS最强负面预测因素(P=.005;HR 2.9);2016年后治疗显著预测OS(P=.002;HR 0.27)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Central nervous system (CNS) involvement is a rare and aggressive complication of multiple myeloma (MM). We identified 54/4352 MM patients (1.2%), who developed CNS-MM between 2000 and 2022. A matched-control group of MM patients without CNS-MM was used for comparisons. Median age was 63 years. Median time to CNS-MM was 28 months; 6/54 experienced CNS-MM at MM diagnosis. Abnormal lactate dehydrogenase (LDH), high-risk cytogenetics, and extramedullary involvement (EMI), that is, soft tissue plasmacytomas and/or plasma cell leukemia (PCL), were more frequent in CNS-MM versus controls (p < .05); 13/54 had PCL at CNS-MM. The majority had leptomeningeal infiltration (LMI) (66%); 26% had CNS-MM without systemic myeloma; EMI was the strongest predictor for CNS-MM (OR: 6.3). Median overall survival (OS) of CNS-MM patients versus controls was 43 months (95% CI: 32-54) versus 60 months (95% CI: 38-82) (p < .001); treatment of CNS-MM included mainly bortezomib/thalidomide/chemotherapy whereas 20% received novel drugs/immunotherapy combinations; 28 patients underwent cerebrospinal fluid infusions; EMI was the strongest negative predictor for post CNS-MM OS (p = .005; HR: 2.9). Treatment after 2016 predicted significantly for OS (p = .002; HR: 0.27). Median post CNS-MM OS was 4 months (95% CI: 2.6-5.4); in patients treated after 2016 median OS was 12 months. In conclusion, we have demonstrated in this large real-world series that survival of CNS-MM remains poor; however, there is a positive impact of treatment after 2016, related to the efficacy of modern anti-myeloma therapy; EMI significantly increases the probability to develop CNS-MM and the risk of post CNS-MM death, indicating a potential need for CNS prophylaxis for those patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Katodritou E, Dalampira D, Delimpasi S, et al. Central nervous system multiple myeloma: A real-world multi-institutional study of the Greek Myeloma Study Group. Am J Hematol. 2024. PMID: 38953456. doi:10.1002/ajh.27425

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。